CTIS2022-501360-18-00招募中1 期
Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-DoubletChemotherapy in Early Stage NSCLC - CA209-816
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 386
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Early stage (IB - IIIA), operable non-small cell lung cancer, confirmed in tissue., Lung function capacity capable of tolerating the proposed lung surgery, Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1., Available tissue of primary lung tumor.
排除标准
- •Presence of locally advanced, inoperable or metastatic disease., Participants with active, known or suspected autoimmune disease., Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors).
研究者
相似试验
进行中（未招募）
1 期
A Neoadjuvant Study of Nivolumab plus Ipilimumab or Nivolumab plus Chemotherapy versus Chemotherapy alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816)EUCTR2016-003536-21-HUBristol-Myers Squibb International Corporation642
进行中（未招募）
1 期
A Neoadjuvant Study of Nivolumab plus Ipilimumab or Nivolumab plus Chemotherapy versus Chemotherapy alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816)EUCTR2016-003536-21-GRBristol-Myers Squibb International Corporation350
进行中（未招募）
1 期
A Neoadjuvant Study of Nivolumab plus Ipilimumab or Nivolumab plus Chemotherapy versus Chemotherapy alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816)Early Stage Non-Small Cell Lung Cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-003536-21-ROBristol-Myers Squibb International Corporation642
进行中（未招募）
1 期
A Neoadjuvant Study of Nivolumab and Ipilimumab compared to Chemotherapy Doublet in Early Stage Non-Small Cell Lung Cancer (NSCLC).Early Stage Non-Small Cell Lung Cancer (NSCLC)MedDRA version: 19.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-003536-21-ESBristol-Myers Squibb International Corporation326
已完成
3 期
A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor O-6-methylguanine DNA methyltransferase) Glioblastoma.GlioblastomaNL-OMON47552Bristol-Myers Squibb24